Abstract:Importance: US health expenditures have been growing at an unsustainable rate, while health inequities and poor outcomes persist. Targeting social determinants of health (SDOH) may contribute to identifying and controlling health care expenditures. Objective: To determine whether SDOH are associated with US health care expenditures by Medicare, Medicaid, and private insurers. Design, setting, and participants: Cross-sectional study of adults, representing the US civilian, noninstitutionalized population with Medicare, Medicaid, or private coverage, from the 2021 Medical Expenditure Panel SDOH Survey. Data analysis was conducted from October 2023 to April 2024. Exposure: SDOH as individual-level, health-related social needs categorized by Healthy People 2030 domains: (1) educational access and quality, (2) health care access and quality, (3) neighborhood and built environment,(4) economic stability, and (5) social and community context. Main outcomes and measures: The primary outcome was health care expenditures (US dollars) by Medicare, Medicaid, and private insurers. A 2-part econometric model (probit regression model and generalized linear model with gamma distribution) was used. Results: Among the 14 918 insured adults in the analytic sample (mean [SD] age, 52.5 [17.9] years; 8471 female [56.8%]), the majority had middle to high family income (10 524 participants [70.5%]) and were privately insured (10 227 participants [68.5%]). Annual median (IQR) expenditure was $1648 ($389-$7126) for Medicaid, $3643 ($1321-$10 519) for Medicare, and $1369 ($456-$4078) for private insurers. Educational attainment and social isolation were associated with Medicaid expenditures. Medicaid beneficiaries with a high school diploma or general educational development certificate had on average (mean difference) $2245.39 lower annual Medicaid expenditures (95% CI, -$3700.97 to -$789.80) compared with beneficiaries with less than high school attainment. Compared with those who never felt isolated, Medicaid beneficiaries who often felt isolated had on average $2706.94 (95% CI, $1339.06-$4074.82) higher annual Medicaid expenditures. Health care access, built environment, and economic stability were associated with Medicare expenditures. Medicare beneficiaries living in neighborhoods with lower availability of parks had on average $5959.27 (95% CI, $1679.99 to $10 238.55) higher annual Medicare expenditures. Medicare beneficiaries who were very confident in covering unexpected expenses had on average $3743.98 lower annual Medicare expenditures (95% CI, -$6500.68 to -$987.28) compared with those who were not confident. Medical discrimination and economic stability were associated with private expenditures. Private insurance beneficiaries who experienced medical discrimination had on average $2599.93 (95% CI, $863.71-$4336.15) higher annual private expenditures compared with those who did not. Private beneficiaries who were contacted by debt collections in the past year had on average $2033.34 (95% CI, $896.82 to $3169.86) higher annual private expenditures compared with those who were not contacted. Conclusions and relevance: In this cross-sectional study of 14 918 insured adults, individual-level SDOH were significantly associated with US health care expenditures by Medicare, Medicaid, and private insurers. These findings may inform health insurers and policymakers to incorporate SDOH in their decision-making practices to identify and control health care expenditures, advancing health equity.

Per-Prescription Drug Expenditure by Source of Payment and Income Level in the United States, 1997 to 2015

Prescription Drugs Prices and Source of Payments in the US from 1997 to 2015

The Relationship Between Medical Insurance Coverage and Medication Payments in the US from 1997 to 2015

Out-Of-Pocket Spending and Financial Burden of Prescription Drugs for Diabetes: 2007-2010

The effect of insurance type on prescription drug use and expenditures among elderly Medicare beneficiaries

Estimating Rebates and Other Discounts Received by Medicare Part D

Use and Cost Patterns of Antihypertensive Medications in the United States From 1996 to 2021

Trends in Inhaler Prescriptions and Associated Cost in the United States From 2014 to 2018: An Analysis From the Medicare Part D Database

Spending on and Use of Clinician-Administered Drugs in Medicare

Association between changes in prices and out‐of‐pocket costs for brand‐name clinician‐administered drugs

Hypertension-Associated Expenditures Among Privately Insured US Adults in 2021

Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019

Population characteristics, use, and spending on sole‐source, off‐patent drugs among commercial insurance members in the United States—An analysis of outpatient claims data at a single health plan

High-Expenditure Pharmaceutical Use Among Children in Medicaid

Affordability and adherence gains for Medicare Part D low-income subsidy recipients when low-income subsidy benefits expanded in 2024

Hypertension-associated Medical Expenditures Among Privately Insured US Individuals Aged 18 to 64 Years in 2021

Medicare beneficiaries' out-of-pocket costs for commonly used generic drugs, 2009-2017

Changes in Health Care and Prescription Medication Affordability in the US During the COVID-19 Pandemic

Use of Pharmacy Sales Data to Assess Changes in Prescription- and Payment-Related Factors that Promote Adherence to Medications Commonly Used to Treat Hypertension, 2009 and 2014

Social Determinants of Health and US Health Care Expenditures by Insurer

Consumer Out-Of-Pocket Drug Prices Grew Faster Than Prices Faced By Insurers After Accounting For Rebates, 2007-20